Fiona Powrie - Selected Publications#

H-factor: 70

1. Powrie F, Mason D. 1990. OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset. J Exp Med 172: 1701-8

This paper shows in vivo that phenotypically distinct subsets of CD4 T cells induce or prevent immune pathology, and contributes to the foundations of the regulatory T cell field. Citations = 274

2. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994;1:553-562.

This paper provides the first in vivo evidence that blockade of TNF-alpha or IFN-gamma ameliorates chronic colitis. Citations = 809

3. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. 1999. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190: 995-1004
This paper was the first to show Tregs suppress inflammatory responses to intestinal antigens through IL-10 secretion. Citations = 1076

4. Read S, Malmstrom V, Powrie F. 2000 Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192:295-302.
Identification of a key role for CTLA4 in Treg mediated control of intestinal inflammation. Citations = 1561

5. Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R, Robinson N, Buonocore S, Tlaskalova-Hogenova H, Cua DJ, Powrie F. 2006. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25: 309-18
This study showed a compartmentalized role of IL-23 in driving mucosal but not systemic inflammation identifying IL-23 as a therapeutic target in human IBD. Citations = 382

6. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, Powrie F. 2007. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 204: 1757-64
This paper contributed to the concept that the intestine is a peripheral site of Treg induction and defined the factors that induce intestinal Tregs. Citations = 1326

7. Ahern PP, Schiering C, Buonocore S, McGeachy MJ, Cua DJ, Maloy KJ, Powrie F. 2010. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33: 279-88
This paper shows IL-23 induces intestinal inflammation through direct activity on T cells to enhance inflammatory Th17 cells responses while limited suppressor T cell activity. Citations = 492

8. Buonocore S, Ahern PP, Uhlig HH, Ivanov, II, Littman DR, Maloy KJ, Powrie F. 2010. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464: 1371-5
The paper characterises a unique population of colitogenic IL-23-responsive innate lymphoid cells, providing insight into disease mechanisms and linking innate lymphoid cells with immune pathology. Citations = 412

9. Geremia A, Arancibia-Carcamo CV, Fleming MP, Rust N, Singh B, Mortensen NJ, Travis SP, Powrie F. 2011. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 208: 1127-33
This shows IL-23-responsive innate lymphoid cells characterised by Buonocore et al (2010) accumulate in the intestine of patients with inflammatory bowel disease. Citations = 157

10. Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert EA, Pott J, Griseri T, Bollrath J, Hegazy AN, Harrison OJ, Owens BM, Lohning M, Belkaid Y, Fallon PG, Powrie F. 2014. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513: 564-8
This paper reports IL-33 enhances protective Treg responses in the gut in response to tissue damage, and shows this pathway is inhibited by pro-inflammatory IL-23. Citations = 78